About
Small Molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalVirginia, DC, DE & Maryland
Team (2)
Clinical Trials (23)
View allTotal Trials
23
As Lead Sponsor
22
As Collaborator
1
Total Enrollment
833
By Phase
PHASE1/PHASE2: 2PHASE1: 7PHASE2: 14
By Status
COMPLETED: 21RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline22 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07017725Lead Sponsor
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
PHASE1/PHASE2Recruiting
75 participants
Started: Jan 3, 2025 · Completed: Dec 30, 2026
NCT05438394Collaborator
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
PHASE1Unknown
24 participants
Started: Oct 13, 2022 · Completed: Dec 31, 2023
NCT04758767Lead Sponsor
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
PHASE1Completed
10 participants
Started: Mar 22, 2021 · Completed: Jan 19, 2023
NCT02234986Lead Sponsor
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
PHASE2Completed
35 participants
Started: Oct 31, 2015 · Completed: Jun 30, 2018
NCT01639248Lead Sponsor
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
PHASE2Completed
41 participants
Started: Jul 31, 2012 · Completed: Jun 30, 2017
Funding History (1)
D
Jul 15, 2024
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...